Online inquiry

IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5076MR)

This product GTTS-WQ5076MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CSF2RA gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001161529.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1438
UniProt ID P15509
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5076MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3500MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAN-2401
GTTS-WQ8596MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ5525MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ9970MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA KBSA301
GTTS-WQ15004MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ1273MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-414
GTTS-WQ7804MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GS-HIV
GTTS-WQ6838MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DT-IL-3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW